BR112017016388A2 - cenicriviroc para o tratamento da fibrose - Google Patents
cenicriviroc para o tratamento da fibroseInfo
- Publication number
- BR112017016388A2 BR112017016388A2 BR112017016388-8A BR112017016388A BR112017016388A2 BR 112017016388 A2 BR112017016388 A2 BR 112017016388A2 BR 112017016388 A BR112017016388 A BR 112017016388A BR 112017016388 A2 BR112017016388 A2 BR 112017016388A2
- Authority
- BR
- Brazil
- Prior art keywords
- cenicriviroc
- fibrosis
- treatment
- peritonitis
- solvate
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 2
- PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 title abstract 2
- 229950011033 cenicriviroc Drugs 0.000 title abstract 2
- 230000004761 fibrosis Effects 0.000 title abstract 2
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 208000018631 connective tissue disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 231100000753 hepatic injury Toxicity 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 206010034674 peritonitis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114304P | 2015-02-10 | 2015-02-10 | |
| US62/114,304 | 2015-02-10 | ||
| PCT/US2015/051467 WO2016130179A1 (en) | 2015-02-10 | 2015-09-22 | Cenicriviroc for the treatment of fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017016388A2 true BR112017016388A2 (pt) | 2018-03-27 |
Family
ID=56614560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017016388-8A BR112017016388A2 (pt) | 2015-02-10 | 2015-09-22 | cenicriviroc para o tratamento da fibrose |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20180110754A1 (https=) |
| EP (1) | EP3256124B1 (https=) |
| JP (2) | JP6676660B2 (https=) |
| KR (1) | KR20170113596A (https=) |
| CN (1) | CN107405403B (https=) |
| AU (1) | AU2015382376B2 (https=) |
| BR (1) | BR112017016388A2 (https=) |
| CA (1) | CA2975445A1 (https=) |
| ES (1) | ES2864767T3 (https=) |
| HK (1) | HK1247558A1 (https=) |
| IL (1) | IL253617A0 (https=) |
| MX (1) | MX2017010277A (https=) |
| RU (1) | RU2722641C2 (https=) |
| SG (1) | SG11201706028RA (https=) |
| WO (1) | WO2016130179A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20030329A1 (es) | 2001-08-08 | 2003-05-12 | Takeda Chemical Industries Ltd | Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo |
| JP6716568B2 (ja) | 2014-12-23 | 2020-07-01 | トビラ セラピューティクス， インコーポレイテッド | セニクリビロックの製造方法及び関連類似体 |
| JP2019520427A (ja) | 2016-06-21 | 2019-07-18 | トビラ セラピューティクス， インコーポレイテッド | 精製されたセニクリビロク及びセニクリビロク製造のための精製された中間体 |
| WO2022235440A1 (en) * | 2021-04-21 | 2022-11-10 | The United States Government As Represented By The Department Of Veterans Affairs | Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2 |
| CN116270633A (zh) * | 2023-03-03 | 2023-06-23 | 神经肌肉骨骼再生医学中心有限公司 | 马拉韦罗在制备治疗肌肉退行性疾病的药物中的用途 |
| CN119954974B (zh) * | 2025-04-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞，其制备方法及抗纤维化的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2249027A (en) * | 1990-10-23 | 1992-04-29 | Fujisawa Pharmaceutical Co | Use of macrolide compounds for hepatic failure |
| PE20030329A1 (es) | 2001-08-08 | 2003-05-12 | Takeda Chemical Industries Ltd | Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo |
| WO2006059716A1 (ja) | 2004-12-03 | 2006-06-08 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| US8148356B2 (en) * | 2005-08-24 | 2012-04-03 | Cumberland Pharmaceuticals, Inc. | Acetylcysteine composition and uses therefor |
| WO2013000922A1 (en) * | 2011-06-27 | 2013-01-03 | Universite Pierre Et Marie Curie (Paris 6) | Ccr2 antagonist peptides |
| JP6263815B2 (ja) * | 2013-03-05 | 2018-01-24 | 国立大学法人 岡山大学 | 細胞死抑制剤及びその製造方法 |
| CN105263498B (zh) * | 2013-05-15 | 2019-04-26 | 妥必徕疗治公司 | 赛尼克韦罗组合物及其制备和使用方法 |
| KR101669124B1 (ko) * | 2013-07-11 | 2016-10-25 | 서울대학교병원 | 인간 배아줄기세포에서 유래된 중간엽 줄기세포를 유효성분으로 함유하는 간섬유화 또는 간경화 예방 및 치료용 조성물 |
-
2015
- 2015-09-22 BR BR112017016388-8A patent/BR112017016388A2/pt not_active Application Discontinuation
- 2015-09-22 MX MX2017010277A patent/MX2017010277A/es unknown
- 2015-09-22 CN CN201580076576.9A patent/CN107405403B/zh not_active Expired - Fee Related
- 2015-09-22 WO PCT/US2015/051467 patent/WO2016130179A1/en not_active Ceased
- 2015-09-22 US US15/549,958 patent/US20180110754A1/en not_active Abandoned
- 2015-09-22 JP JP2017560462A patent/JP6676660B2/ja not_active Expired - Fee Related
- 2015-09-22 CA CA2975445A patent/CA2975445A1/en not_active Abandoned
- 2015-09-22 RU RU2017130289A patent/RU2722641C2/ru active
- 2015-09-22 SG SG11201706028RA patent/SG11201706028RA/en unknown
- 2015-09-22 EP EP15882259.3A patent/EP3256124B1/en not_active Not-in-force
- 2015-09-22 ES ES15882259T patent/ES2864767T3/es active Active
- 2015-09-22 HK HK18106984.5A patent/HK1247558A1/zh unknown
- 2015-09-22 KR KR1020177023821A patent/KR20170113596A/ko not_active Ceased
- 2015-09-22 AU AU2015382376A patent/AU2015382376B2/en not_active Expired - Fee Related
-
2017
- 2017-07-23 IL IL253617A patent/IL253617A0/en unknown
-
2019
- 2019-02-26 US US16/285,867 patent/US20190343806A1/en not_active Abandoned
-
2020
- 2020-03-12 JP JP2020042730A patent/JP2020111586A/ja active Pending
- 2020-06-03 US US16/891,979 patent/US20200360347A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL253617A0 (en) | 2017-09-28 |
| JP2020111586A (ja) | 2020-07-27 |
| EP3256124B1 (en) | 2020-12-23 |
| KR20170113596A (ko) | 2017-10-12 |
| US20180110754A1 (en) | 2018-04-26 |
| AU2015382376B2 (en) | 2021-07-01 |
| AU2015382376A1 (en) | 2017-08-17 |
| MX2017010277A (es) | 2017-12-07 |
| US20190343806A1 (en) | 2019-11-14 |
| JP6676660B2 (ja) | 2020-04-08 |
| JP2018505218A (ja) | 2018-02-22 |
| RU2017130289A3 (https=) | 2019-04-22 |
| CN107405403A (zh) | 2017-11-28 |
| HK1247558A1 (zh) | 2018-09-28 |
| ES2864767T3 (es) | 2021-10-14 |
| EP3256124A1 (en) | 2017-12-20 |
| CA2975445A1 (en) | 2016-08-18 |
| CN107405403B (zh) | 2021-04-20 |
| EP3256124A4 (en) | 2018-09-26 |
| US20200360347A1 (en) | 2020-11-19 |
| WO2016130179A1 (en) | 2016-08-18 |
| SG11201706028RA (en) | 2017-08-30 |
| RU2017130289A (ru) | 2019-03-12 |
| RU2722641C2 (ru) | 2020-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| MX2016012262A (es) | Cenicriviroc para el tratamiento de fibrosis. | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| BR112016017041A2 (pt) | Proteína isolada tendo atividade de fosfatase, polinucleotídeo, vetor, célula hospedeira, método para produzir uma proteína e composição | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| BR112015015891A8 (pt) | Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| WO2015153959A3 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
| EA201790787A1 (ru) | Снижение вязкости фармацевтических составов | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
| MX387235B (es) | Derivados de pirazolopiridina y su uso en terapia | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| BR112017005209A2 (pt) | compostos moduladores de pirrolopiridina substituída por metila e trifluorometila de rorc2 e seu uso | |
| BR112017016388A2 (pt) | cenicriviroc para o tratamento da fibrose | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX2016014859A (es) | Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas. | |
| BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |